The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a more substantial loss in body mass and benefit metabolic health, particularl